



01 PT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 8716**  
Daiji NAKA et al. : Docket No. 2001\_1797A  
Serial No. 10/000,096 : Group Art Unit 1644  
Filed December 4, 2001 :

#9  
JN.  
10/3/07

SPECIFIC ANTIBODY DIRECTED TO  
ACTIVE HEPATOCYTE GROWTH  
FACTOR ACTIVATOR AND METHOD  
FOR USING THE SAME

RECEIVED  
TECH CENTER 1600 2007

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of [X] the references listed on attached form PTO-1449 and/or [X] the additional information identified below in paragraph 3. A legible copy of each reference listed on the form PTO-1449 and each U.S. patent application listed below is enclosed, except a copy is not provided for each reference previously cited by or submitted to the Patent Office in prior parent application Serial No.

1a. [X] This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

**and thus no certification and/or fee is required.**

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**  
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and  
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or  
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☒ The Examiner is requested to note that the cited references XP 000197750 and XP 0020397579 cited in the enclosed Search Report were previously cited in the IDS

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☒ A European search report citing one or more of the references is enclosed.

Respectfully submitted,

Daiji NAKA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/lgs  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
April 23, 2002

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 23, 2002

ATTY DOCKET NO.  
2001\_1797ASERIAL NO.  
10/000,096APPLICANT  
Daiji NAKA et al.FILING DATE  
December 4, 2001GROUP  
1644

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DIPE JC/SP	AA						
APR 23 2002	AB						
PATENT & TRADEMARK OFFICE	AC						
	AD						
	AE						
	AF						
	AG						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AH	0596524	05/1994	EP			
	AI						
	AJ						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	T. Shimomura et al., "Activation of the Zymogen of Hepatocyte Growth Factor Activator by Thrombin", Journal of Biological Chemistry, American Society of Biological Chemists, 10/1993, XP000197750					
	AL	Patent Abstracts of Japan vol. 018, no. 420, 08/1994 & JP 06130066A, 05/1994 ABSTRACT					
	AM	T. Shimomura et al., "Activation of Hepatocyte Growth Factor by Two Homologous Proteases Blood-Coagulation Factors XIIa and Hepatocyte Growth Factor Activator", European Journal of Biochemistry, 04/1995, XP001062759					
	AN	H. Kataoka et al., "Activation of Hepatocyte Growth Factor/Scatter Factor in Colorectal Carcinoma", Cancer Research, 11/2000, XP001065551					

Shimomura T, et al. Activation of hepatocyte growth factor in the injured pancreas is mediated by hepatocyte growth factor activator. Journal of Biological Chemistry, 02 1996, XP002039579

EXAMINER

DATE CONSIDERED